Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07680946 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Eligibility criteria expanded, about 8 words
  2. Primary completion date: Dec 1, 2028 to Dec 12, 2028 Start date: Jul 3, 2026 to Jul 27, 2026v3 Show 1 more changeShow less
    • Start date: Jul 3, 2026 to Jul 27, 2026
  3. Recruitment opened Study sites: 0 to 2 · Start date changed from estimate of Jul 6, 2026 to Jul 3, 2026v2 Show 2 more changesShow less
    • Study sites: 0 to 2
    • Start date changed from estimate of Jul 6, 2026 to Jul 3, 2026
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main objective of this Phase 2 study is to assess the efficacy of ublituximab as measured by Positive and Negative Syndrome Scale (PANSS) total score in participants with schizophrenia.
Trial Details
NCT Number NCT07680946
Lead Sponsor TG Therapeutics, Inc.
Conditions Schizophrenia
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov